MiNK Therapeutics, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 30.21 million compared to USD 16.24 million a year ago. Basic loss per share from continuing operations was USD 1.16 compared to USD 0.67 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 USD | -0.96% | +14.44% | -3.74% |
May. 14 | Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.74% | 36.09M | |
+34.67% | 50.85B | |
+0.62% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+10.76% | 26.11B | |
-21.57% | 19.13B | |
+8.75% | 13.05B | |
+26.96% | 12.16B | |
+24.35% | 12.08B |
- Stock Market
- Equities
- INKT Stock
- News MiNK Therapeutics, Inc.
- MiNK Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021